Zydus Pharmaceuticals (usa) Inc: FDA regulatory profile

Zydus Pharmaceuticals (usa) Inc appears in 3 indexed U.S. FDA records: 3 recall records, naming 3 distinct products. Latest dated event: a recall record dated 2026-08-12. Observations run 2026-05-27 to 2026-08-12 — 77 days, 3 dated records across 1 calendar year, busiest 2026 with 3. Recalls: 3 Class II (100%); 3 ongoing by lifecycle status, reported 2026-05-27 to 2026-08-12; 3 with an FDA recall number, 3 with an initiation date, across 1 state, grouped into 2 FDA recall events. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. Recall records: Mirabegron Extended-Release Tablets (D-0745-2026, Class II, 2026-08-12), Erythromycin Tablets (D-0544-2026, Class II, 2026-05-27) and Erythromycin Tablets (D-0545-2026, Class II, 2026-05-27). Recalling-firm addresses are recorded in NJ. Its recall lines are grouped by the FDA into 2 event identifiers: 98870 and 99563. Distribution is recorded in the source as Nationwide in the USA and Nationwide within the U.S.

Regulatory snapshot

Indexed records 3
Recall records 3
Shortage entries 0
Source rows filed 0
Approval records 0
Current shortages 0
Resolved shortages 0
Discontinued shortages 0
Unique products 3
Recall classifications Class II: 3
Recall statuses Ongoing: 3
First observed 2026-05-27
Latest observed 2026-08-12
Latest event type recall
Dated observations 3
Years covered 1
Span (days) 77
Busiest year 2026 (3 records)
Recall states 1
With recall number 3 of 3
FDA recall events 2
Related firms / shortages 0 / 0

Counts, not a rating. Coverage-limited activity signals over the ingested window — never reputational scores or judgements about the firm or its products.

Record breakdown

DimensionValueRecordsShare
Recall classificationClass II3100%
Recall statusOngoing3100%

Recall history (3)

Every enforcement report attributed to this firm, newest first. Classification is the FDA's severity tier, status its lifecycle position — neither is a safety statement.

Product (as published)Recall numberClassificationStatusReportedInitiated
Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zyd D-0745-2026 Class II Ongoing 2026-08-12 2026-08-05
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus D-0544-2026 Class II Ongoing 2026-05-27 2026-04-29
Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus D-0545-2026 Class II Ongoing 2026-05-27 2026-04-29
FDA recall eventRecordsClassification(s)First reportedLast reported
988702Class II2026-05-272026-05-27
995631Class II2026-08-122026-08-12

Browse the wider classification index: Class II recalls.

Products and drugs named (3)

De-duplicated by record entity, not raw source row.

Source limitations

Built from the 3 ingested FDA records for this firm (3 recall, 0 shortage, 0 approval) — not its full regulatory history. The window is finite and can lag the live record, and alternate spellings of a firm name may sit under separate profiles. Confirm details at the linked official source. Regulatory information only: no safety assessment, no recommendation.

Where to go next

Source & provenance

Official source
https://open.fda.gov/apis/drug/enforcement/
Source dataset
openFDA (enforcement + shortages + Drugs@FDA)
Publication date
Not available
Ingested
2026-08-22

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.